Pfizer announces $3 million grants program to further clinical research in advanced breast cancer
- Details
- Category: Pfizer
Pfizer Inc. today announced the launch of a competitive, peer-reviewed grants program to support clinical research projects investigating IBRANCE® (palbociclib) in advanced breast cancer.
Eureka Therapeutics Inc. and Boehringer Ingelheim announce a collaboration to identify next generation antibodies for cancer treatment
- Details
- Category: Boehringer Ingelheim
Eureka Therapeutics Inc. and Boehringer Ingelheim announced have entered into a research agreement for the discovery of novel therapeutic antibodies in oncology. Eureka Therapeutics will apply its proprietary human sequence antibody libraries and its unique technology platform to identify antibodies recognizing intracellular proteins, which represent approximately 90% of cancer-specific targets.
AstraZeneca provides update on brodalumab development programme
- Details
- Category: AstraZeneca
Amgen today announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab, an investigational IL-17 receptor inhibitor in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis.
Novartis drug Afinitor® extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumors
- Details
- Category: Novartis
Novartis announced today that the Phase III study of Afinitor® (everolimus) tablets plus best supportive care in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met its primary endpoint: significant extension of progression-free survival (PFS) compared to placebo plus best supportive care[1].
Boehringer Ingelheim acquires Pharmaxis' phase 1 anti-inflammatory drug candidate
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and pharmaceutical company Pharmaxis (ASX: PXS) announce that Boehringer Ingelheim has exercised its option and acquired the investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH and to prevent its consequences.
AstraZeneca to invest in new biologics manufacturing facility in Södertälje, Sweden
- Details
- Category: AstraZeneca
AstraZeneca today announced that it plans to invest approximately $285 million in a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The new plant will be focused on filling and packaging of protein therapeutics.
AstraZeneca and Montreal Heart Institute to screen 80,000 samples for cardiovascular and diabetes genetic traits
- Details
- Category: AstraZeneca
AstraZeneca today announced a collaboration with the Montreal Heart Institute (MHI) in Quebec, Canada, to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications and treatment outcomes.
More Pharma News ...
- Pfizer acquires minority interest in AM-Pharma; secures option to acquire company
- Xarelto® approved in China across three indications in the area of venous and arterial thromboembolism
- Kåre Schultz appointed new president and CEO of Lundbeck
- Strong start to the year for Bayer
- FDA grants Priority Review for potential new indication for Brilinta
- Boehringer Ingelheim positioned for future growth with product launches
- AstraZeneca and Innate Pharma announce global co-development and commercialisation collaboration for IPH2201 in immuno-oncology